TFF PHARMACEUTICALS, INC. Research and Development in Process
TFF PHARMACEUTICALS, INC. reported Research and Development in Process of $87.59 thousand for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2022-11-14
- TFF PHARMACEUTICALS, INC. research and development in process for the quarter ending 2022-09-30 was $87.59K, a 75.17% increase year-over-year.
- TFF PHARMACEUTICALS, INC. research and development in process for the quarter ending 2022-06-30 was $28.00K, a 1413.73% increase year-over-year.
- TFF PHARMACEUTICALS, INC. research and development in process for the quarter ending 2022-03-31 was $67.44K, a 177.34% increase year-over-year.
- TFF PHARMACEUTICALS, INC. research and development in process for the quarter ending 2021-09-30 was $50.00K.
- TFF PHARMACEUTICALS, INC. research and development in process for fiscal 2020 was $1.82M, a 86.69% increase from fiscal 2019.
- TFF PHARMACEUTICALS, INC. research and development in process for fiscal 2019 was $977.00K.
| Period end | Research and Development in Process 3 month | Research and Development in Process 6 month | Research and Development in Process 6 month as first filed | Research and Development in Process 9 month | Research and Development in Process 12 month |
|---|---|---|---|---|---|
| 2022-09-30 | $87.59K 10-Q · filed 2022-11-14 | $115.59K derived: sum of 2 quarters · filed 2022-11-14 | $183.03K 10-Q · filed 2022-11-14 | ||
| 2022-06-30 | $28.00K 10-Q · filed 2022-08-11 | $95.44K 10-Q · filed 2022-08-11 | |||
| 2022-03-31 | $67.44K 10-Q · filed 2022-05-11 | ||||
| 2021-09-30 | $50.00K 10-Q · filed 2022-11-14 | $51.85K derived: sum of 2 quarters · filed 2022-11-14 | $76.17K 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | $1.85K 10-Q · filed 2022-08-11 | $1.85K 10-Q · filed 2022-08-11 | $26.16K 10-Q · filed 2021-08-12 | ||
| 2021-03-31 | $24.32K 10-Q · filed 2022-05-11 | ||||
| 2020-12-31 | $1.82M 10-K · filed 2021-03-10 | ||||
| 2019-12-31 | $977.00K 10-K · filed 2021-03-10 |